A.P. Pharma, Inc. Initiates APF530 Phase 3 Clinical Trial

REDWOOD CITY, Calif.--(BUSINESS WIRE)--April 27, 2006--A.P. Pharma, Inc. (NASDAQ:APPA - News), a specialty pharmaceutical company, today reported that the protocol for the Phase 3 clinical trial for APF530 has been finalized in cooperation with U.S. Food & Drug Administration (FDA) officials. Additionally, the company has received approval for the Phase 3 protocol for APF530 from the governing IRB that is responsible for overseeing the study. IRB approval of the protocol is the final step before initiation of the pivotal study.